MedTrace Logo

R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma

NCT06594640 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 108

Last updated 2025-05-14

No results posted yet for this study

Summary

This is a prospective clinical study to evaluate the safety and efficacy of R-CMOP in patients with newly diagnosed diffuse large B-cell lymphoma

Conditions

  • Diffuse Large B-cell Lymphoma

Interventions

DRUG

Mitoxantrone Hydrochloride Liposome

assigned dose according to the 3+3 dose-escalation design in part 1, RP2D in part 2, D2

DRUG

Rituximab (R)

375mg/m2, D2

DRUG

Cyclophosphamide (CTX)

750mg/m2, D2

DRUG

Vincristin

1.2mg/m2, maximum 2mg， D2

DRUG

Prednisolone

60mg/m2, D2-6

Sponsors & Collaborators

  • Institute of Hematology & Blood Diseases Hospital, China

    lead OTHER

Principal Investigators

  • Lugui Qiu, Professor · Institute of Hematology & Blood Diseases Hospital, China

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-30
Primary Completion
2026-06-30
Completion
2027-07-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06594640 on ClinicalTrials.gov